• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.

作者信息

Ikumi Kyoko, Torii Kan, Sagawa Yoko, Kanayama Yoshifumi, Nakada Aya, Nishihara Haruna, Morita Akimichi

机构信息

Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

J Dermatol. 2022 Apr;49(4):e125-e126. doi: 10.1111/1346-8138.16286. Epub 2021 Dec 27.

DOI:10.1111/1346-8138.16286
PMID:34961971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9304264/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aadc/9304264/52ce9f0a3195/JDE-49-e125-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aadc/9304264/52ce9f0a3195/JDE-49-e125-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aadc/9304264/52ce9f0a3195/JDE-49-e125-g001.jpg

相似文献

1
Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.磷酸二酯酶4抑制剂阿普司特可改善银屑病患者的胰岛素抵抗。
J Dermatol. 2022 Apr;49(4):e125-e126. doi: 10.1111/1346-8138.16286. Epub 2021 Dec 27.
2
Apremilast for the management of moderate to severe plaque psoriasis.阿普米拉斯用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2017 Apr;10(4):349-360. doi: 10.1080/17512433.2017.1293519. Epub 2017 Feb 17.
3
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.阿普司特，一种口服磷酸二酯酶4抑制剂，用于治疗日本中重度斑块状银屑病患者：2b期随机对照试验的疗效、安全性和耐受性结果
J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9.
4
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.阿普米司特：一种用于治疗银屑病和银屑病关节炎的新型口服药物。
Am J Clin Dermatol. 2018 Feb;19(1):23-32. doi: 10.1007/s40257-017-0302-0.
5
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.阿普米司特治疗中重度斑块状银屑病的药效学评估。
Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1121-8. doi: 10.1080/17425255.2016.1206886. Epub 2016 Jul 14.
6
Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.阿普司特治疗中度至重度银屑病的真实世界单中心经验。
Clin Exp Dermatol. 2017 Aug;42(6):675-676. doi: 10.1111/ced.13150. Epub 2017 Jun 16.
7
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.银屑病和银屑病关节炎管理的新进展：聚焦阿普斯特
Drug Des Devel Ther. 2013;7:201-10. doi: 10.2147/DDDT.S32713. Epub 2013 Mar 27.
8
Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.阿普米司特治疗银屑病临床疗效的潜在机制
J Drugs Dermatol. 2018 Aug 1;17(8):835-840.
9
Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast.循环单核细胞在接受阿普米司特治疗的中重度斑块状银屑病患者中具有预测性和反应性。
J Invest Dermatol. 2024 Sep;144(9):1963-1974.e13. doi: 10.1016/j.jid.2024.01.034. Epub 2024 Feb 29.
10
Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.银屑病患者中协同细胞因子效应作为阿普斯特反应预测指标
J Allergy Clin Immunol. 2018 Sep;142(3):1010-1013.e6. doi: 10.1016/j.jaci.2018.05.039. Epub 2018 Jun 21.

引用本文的文献

1
Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment.以环磷酸腺苷（cAMP）信号传导和磷酸二酯酶4为靶点治疗肝脏疾病。
Med Chem Res. 2024 Aug;33(8):1339-1353. doi: 10.1007/s00044-024-03267-3. Epub 2024 Jun 26.
2
Characteristics and Burdens of Disease in Patients from Beijing with Generalized Pustular Psoriasis and Palmoplantar Pustulosis: Multicenter Retrospective Cohort Study Using a Regional Database.北京泛发性脓疱型银屑病和掌跖脓疱病患者的疾病特征和负担：使用区域数据库的多中心回顾性队列研究。
Am J Clin Dermatol. 2023 Nov;24(6):991-1002. doi: 10.1007/s40257-023-00807-2. Epub 2023 Jun 29.

本文引用的文献

1
Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.银屑病关节炎与糖尿病：一篇叙述性综述
Rheumatol Ther. 2020 Jun;7(2):271-285. doi: 10.1007/s40744-020-00206-7. Epub 2020 Apr 18.
2
Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice.高血糖与人类和小鼠的银屑病炎症有关。
J Invest Dermatol. 2019 Jun;139(6):1329-1338.e7. doi: 10.1016/j.jid.2019.01.029. Epub 2019 Feb 15.
3
Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.磷酸二酯酶-4抑制作为代谢紊乱的一种治疗策略。
Obes Rev. 2016 May;17(5):429-41. doi: 10.1111/obr.12385. Epub 2016 Mar 21.
4
Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study.银屑病严重程度、合并用药和合并症与糖尿病风险增加的关系：一项全国基于人群的队列研究。
J Am Acad Dermatol. 2014 Apr;70(4):691-698. doi: 10.1016/j.jaad.2013.11.023. Epub 2014 Jan 9.
5
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.磷酸二酯酶 4 抑制剂罗氟司特对初诊 2 型糖尿病患者糖代谢的影响。
J Clin Endocrinol Metab. 2012 Sep;97(9):E1720-5. doi: 10.1210/jc.2011-2886. Epub 2012 Jun 20.